JP6352905B2 - コエンザイムｑ１０を用いた固形腫瘍の治療 - Google Patents

コエンザイムｑ１０を用いた固形腫瘍の治療 Download PDF

Info

Publication number
JP6352905B2
JP6352905B2 JP2015515272A JP2015515272A JP6352905B2 JP 6352905 B2 JP6352905 B2 JP 6352905B2 JP 2015515272 A JP2015515272 A JP 2015515272A JP 2015515272 A JP2015515272 A JP 2015515272A JP 6352905 B2 JP6352905 B2 JP 6352905B2
Authority
JP
Japan
Prior art keywords
cancer
dose
coq10
pharmaceutical composition
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015515272A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015518056A5 (enExample
JP2015518056A (ja
Inventor
ナレイン，ニーブン，ラジン
マクック，ジョン，パトリック
ソン，ポール，ワイ．
Original Assignee
バーグ エルエルシー
バーグ エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バーグ エルエルシー, バーグ エルエルシー filed Critical バーグ エルエルシー
Publication of JP2015518056A publication Critical patent/JP2015518056A/ja
Publication of JP2015518056A5 publication Critical patent/JP2015518056A5/ja
Application granted granted Critical
Publication of JP6352905B2 publication Critical patent/JP6352905B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2015515272A 2012-06-01 2013-05-31 コエンザイムｑ１０を用いた固形腫瘍の治療 Active JP6352905B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261654245P 2012-06-01 2012-06-01
US61/654,245 2012-06-01
PCT/US2013/043785 WO2013181639A1 (en) 2012-06-01 2013-05-31 Treatment of solid tumors using coenzyme q10

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018109093A Division JP2018168164A (ja) 2012-06-01 2018-06-07 コエンザイムｑ１０を用いた固形腫瘍の治療

Publications (3)

Publication Number Publication Date
JP2015518056A JP2015518056A (ja) 2015-06-25
JP2015518056A5 JP2015518056A5 (enExample) 2016-07-21
JP6352905B2 true JP6352905B2 (ja) 2018-07-04

Family

ID=49673946

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015515272A Active JP6352905B2 (ja) 2012-06-01 2013-05-31 コエンザイムｑ１０を用いた固形腫瘍の治療
JP2018109093A Withdrawn JP2018168164A (ja) 2012-06-01 2018-06-07 コエンザイムｑ１０を用いた固形腫瘍の治療
JP2020127877A Active JP7225167B2 (ja) 2012-06-01 2020-07-29 コエンザイムｑ１０を用いた固形腫瘍の治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018109093A Withdrawn JP2018168164A (ja) 2012-06-01 2018-06-07 コエンザイムｑ１０を用いた固形腫瘍の治療
JP2020127877A Active JP7225167B2 (ja) 2012-06-01 2020-07-29 コエンザイムｑ１０を用いた固形腫瘍の治療

Country Status (16)

Country Link
US (3) US20140017317A1 (enExample)
EP (1) EP2854528B8 (enExample)
JP (3) JP6352905B2 (enExample)
KR (2) KR20200118233A (enExample)
CN (1) CN104507308A (enExample)
AU (2) AU2013267166A1 (enExample)
BR (1) BR112014029954A2 (enExample)
CA (2) CA3090268A1 (enExample)
EA (1) EA032345B1 (enExample)
ES (1) ES2761449T3 (enExample)
IL (1) IL236008B (enExample)
IN (1) IN2014DN10734A (enExample)
MX (2) MX369768B (enExample)
NZ (1) NZ702369A (enExample)
SG (1) SG11201407880QA (enExample)
WO (1) WO2013181639A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018168164A (ja) * 2012-06-01 2018-11-01 バーグ エルエルシー コエンザイムｑ１０を用いた固形腫瘍の治療

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102481269B (zh) 2009-05-11 2015-10-07 博格有限责任公司 包含辅酶q10的药物组合物及其制备方法
JP6092844B2 (ja) 2011-04-04 2017-03-08 バーグ エルエルシー 中枢神経系腫瘍の治療方法
BR112015025424A2 (pt) * 2013-04-08 2017-07-18 Berg Llc tratamento de câncer usando terapias de combinação de coenzima q10
MX381399B (es) 2013-09-04 2025-03-12 Berg Llc Formulaciones de coenzima q10 y métodos de uso.
US9996463B2 (en) * 2015-11-10 2018-06-12 International Business Machines Corporation Selection and placement of volumes in a storage system using stripes
WO2017087576A1 (en) * 2015-11-16 2017-05-26 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
US20170255565A1 (en) * 2016-03-02 2017-09-07 Intel Corporation Method and apparatus for providing a contiguously addressable memory region by remapping an address space
WO2018005412A1 (en) * 2016-06-28 2018-01-04 Tien Yang Der Chemoprotective/chemoactive nanodroplets and methods of use thereof
CA3063916A1 (en) * 2017-05-17 2018-11-22 Berg Llc Use of coenzyme q10 formulations in the treatment and prevention of epidermolysis bullosa
CA3239264A1 (en) * 2021-12-01 2023-06-08 Gambro Lundia Ab New dialysis fluid
WO2025087731A1 (en) * 2023-10-24 2025-05-01 Gambro Lundia Ab Compositions comprising insulin and ketones bodies to treat cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US20070104688A1 (en) 2003-02-13 2007-05-10 City Of Hope Small interfering RNA mediated transcriptional gene silencing in mammalian cells
WO2005048925A2 (en) * 2003-11-14 2005-06-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating a neoplastic disease in a subject using inorganic selenium-containing compounds
HRP20130459T1 (en) 2004-01-22 2013-06-30 University Of Miami Topical co-enzyme q10 formulations and methods of use
WO2008069276A1 (ja) * 2006-12-06 2008-06-12 Kaneka Corporation 癌治療剤および発癌抑制剤
US8454945B2 (en) 2007-03-22 2013-06-04 Berg Pharma Llc Topical formulations having enhanced bioavailability
WO2009064738A2 (en) * 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents
EP2229186A2 (en) 2007-12-04 2010-09-22 Alnylam Pharmaceuticals Inc. Carbohydrate conjugates as delivery agents for oligonucleotides
US8247435B2 (en) * 2009-02-19 2012-08-21 Thornthwaite Jerry T Formulations for treating human and animal diseases
CN102481269B (zh) 2009-05-11 2015-10-07 博格有限责任公司 包含辅酶q10的药物组合物及其制备方法
GB0913193D0 (en) 2009-07-29 2009-09-02 Johnson Matthey Plc Deoxygenation process
BR112012022916B1 (pt) * 2010-03-12 2021-11-09 Berg Llc Formulações intravenosas de coenzima q10 (coq10), bem como método de preparação e uso da mesma
US20140239525A1 (en) 2011-06-17 2014-08-28 Board Of Regents, University Of Texas System Inhalable pharmaceutical compositions
US20140017317A1 (en) * 2012-06-01 2014-01-16 Niven Rajin Narain Methods of treatment of solid tumors using coenzyme q10

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018168164A (ja) * 2012-06-01 2018-11-01 バーグ エルエルシー コエンザイムｑ１０を用いた固形腫瘍の治療
JP2020183440A (ja) * 2012-06-01 2020-11-12 バーグ エルエルシー コエンザイムｑ１０を用いた固形腫瘍の治療
JP7225167B2 (ja) 2012-06-01 2023-02-20 バーグ エルエルシー コエンザイムｑ１０を用いた固形腫瘍の治療

Also Published As

Publication number Publication date
IL236008B (en) 2018-08-30
KR20200118233A (ko) 2020-10-14
KR102163948B1 (ko) 2020-10-12
MX369768B (es) 2019-11-21
CA3090268A1 (en) 2013-12-05
HK1208995A1 (en) 2016-03-24
JP2018168164A (ja) 2018-11-01
SG11201407880QA (en) 2014-12-30
US20140017317A1 (en) 2014-01-16
IL236008A0 (en) 2015-02-01
EP2854528A1 (en) 2015-04-08
MX2019013776A (es) 2020-01-30
AU2017202567A1 (en) 2017-05-11
EP2854528B8 (en) 2019-10-23
KR20150022932A (ko) 2015-03-04
EP2854528B1 (en) 2019-09-18
MX2014014492A (es) 2015-05-12
NZ702369A (en) 2016-12-23
AU2017202567B2 (en) 2019-06-13
CA2875150C (en) 2020-10-27
EA201492187A1 (ru) 2015-05-29
EP2854528A4 (en) 2016-03-09
ES2761449T3 (es) 2020-05-19
US20170216223A1 (en) 2017-08-03
CA2875150A1 (en) 2013-12-05
US20220096399A1 (en) 2022-03-31
JP7225167B2 (ja) 2023-02-20
AU2013267166A1 (en) 2014-12-18
EA032345B1 (ru) 2019-05-31
JP2015518056A (ja) 2015-06-25
WO2013181639A8 (en) 2014-12-31
WO2013181639A1 (en) 2013-12-05
IN2014DN10734A (enExample) 2015-09-04
JP2020183440A (ja) 2020-11-12
CN104507308A (zh) 2015-04-08
BR112014029954A2 (pt) 2017-06-27

Similar Documents

Publication Publication Date Title
JP7225167B2 (ja) コエンザイムｑ１０を用いた固形腫瘍の治療
JP6974369B2 (ja) コエンザイムｑ１０併用療法を用いた癌の処置方法
US11452699B2 (en) Method of treating or preventing tumors of the central nervous system
HK1208995B (en) Treatment of solid tumors using coenzyme q10

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160531

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160531

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170328

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170803

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170803

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170912

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171206

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180508

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180607

R150 Certificate of patent or registration of utility model

Ref document number: 6352905

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250